The second messenger cyclic AMP (cAMP) can either stimulate or inhibit programmed cell death (apoptosis). Here, we review examples of cell types that show pro-apoptotic or anti-apoptotic responses to increases in cAMP. We also show that cells can have both such responses, although predominantly having one or the other. Protein kinase A (PKA)-promoted changes in phosphoylation and gene expression can mediate pro-apoptotic responses, such as in murine S49 lymphoma cells, based on evidence that mutants lacking PKA fail to undergo cAMP-promoted, mitochondria-dependent apoptosis. Mechanisms for the anti-apoptotic response to cAMP likely involve Epac (Exchange protein activated by cAMP), a cAMP-regulated effector that is a guanine nucleotide exchange factor (GEF) for the low molecular weight G-protein, Rap1. Therapeutic approaches that activate PKA-mediated pro-apoptosis or that block Epac-mediated anti-apoptotisis may provide a means to enhance cell killing, such as in certain cancers. By contrast, efforts to block PKA or stimulate Epac have the potential to be useful in diseases settings (such as heart failure) associated with cAMP-promoted apoptosis.
Introduction
Cyclic AMP (cAMP) is a well-studied second messenger with >95,000 entries (as of December, 2010) in PubMed. Regulation of cell death is one of the actions of cAMP. Indeed, a PubMed search with the terms "cyclic AMP" and "cell death" reveals >2000 published articles (including 160 reviews) over the past 40 years but none that review the stimulation or inhibition of cell death, in particular, apoptosis (programmed cell death) by cAMP. Moreover, components in the cAMP signaling pathway, including the cAMP effector protein kinase A (PKA), have been proposed as targets to enhance apoptosis, such as in the treatment of certain cancers (e.g., Cross, et al 2000; Lerner et al 2000) . In this article we focus on publications in recent years and summarize pro-and anti-apoptotic responses to cAMP in various cell types, mechanisms for these actions and therapeutic implications of such findings.
cAMP as a regulator of cell death
Even though cAMP was discovered in the late 1950's, the role of cAMP in regulating cell death has been studied much less intensely than other actions, such as regulation of metabolism and various physiological responses. The ability of cAMP to promote cell death was first recognized in the early 1970 's (e.g., Martorana 1971 Basile et al 1973; Pratt and Martin, 1975; Coffino et al 1975; Insel et al 1975) but the full range of cell types subject to this action is still being defined. The initial description of apoptosis occurred at about the same time (Kerr et al 1972) but only in recent years has the regulation of apoptotic cell death by cAMP been studied.
Apoptosis is one form of cell death, the two other major types being autophagy and necrosis, each of which has distinct morphological features and mechanisms. Considerable effort has been directed at distinguishing necrosis from apoptosis (e.g., Walker et al, 1988) . Necrosis is a largely passive phenomenon that follows irreversible injury while apoptosis is an active process that requires numerous proteins and has two primary forms: intrinsic, mitochondrialdependent and extrinsic, resulting from the action of membrane death receptors by extracellular agents such as Fas ligand. The intrinsic pathway involves B-cell lymphoma (Bcl)-related family proteins that have anti-apoptotic (e.g., Bcl-2, Bcl XL ) or pro-apoptotic (e.g., Bax, Bak, BAD, BIM, Bcl XS ) actions that can regulate mitochondrial release of cytochrome c and Smac (second mitochondria-derived activator of caspases/DIABLO (direct IAP-binding protein with low pI). Both intrinsic and extrinsic pathways involve the activation of caspases (cysteinyl aspartate-specific proteinases), enzymes that mediate cell killing. Apoptosis has physiological roles in regulating tissue size and remodeling but also occurs in pathological settings. Characteristic morphological features of apoptosis include condensation of nuclear chromatin and the cytoplasm, fragmentation of the nucleus (in association with internucleosomal cleavage of DNA) and cell budding with eversion of the plasma membrane and generation of membraneous bodies that are disposed of by adjacent cells. The distinctive internucleosomal cleavage of DNA in apoptosis generates electrophoretically observed DNA "ladders" that contrast with the random degradation of DNA that occurs with necrosis.
Few studies have assessed the impact of cAMP on necrosis (e.g., Journot et al, 1998) but there has been recent interest related to cAMP and autophagy--a mechanism by which cells deliver misfolded, ubiquinated proteins for degradation by lysosomes, in particular as a means to supply macromolecules in settings of nutrient deprivation. Its action in such settings has led to the proposal that autophagy is primarily a mechanism for cell survival rather than cell death (e.g., Levine and Yuan 2005) . Numerous studies implicate cAMP in the regulation of autophagy in mammalian cells and lower eukaryotes and suggest that cellular components involved in autophagy can influence cAMP-mediated signal transduction (e. g., Holen et al, 1996; Budovskaya et al, 2005; Stephan et al, 2009; Houslay and Christian, 2010; Chin et al, 2010) .
Cells that show pro-apoptotic responses to cAMP
Increases in cAMP are pro-apoptotic in numerous cell types (Table 1) , including normal cells as well as malignant cells from virtually every tissue. In some cases, the apoptotic responses to cAMP analogs have been assessed whereas in other studies, endogenous cAMP concentrations have been raised by the use of hormones, neurotransmitters, the diterpene forskolin (which activates adenylyl cyclase) or cAMP phosphodiesterase (PDE) inhibitors. Cyclic AMP can also sensitize cells to the pro-apoptotic action of agents, such as DNA damage, that work via non-cAMP pathway components (e.g., Ugland et al 2008) .
Some examples in Table 1 involve individual cell lines or cultured cells; for that reason, we use the term "certain" before several cell types. Of note are the substantial data indicating cAMP-promoted apoptosis in certain lymphoid cells, especially immature lymphoid cells, certain neuronal cells and cardiac myocytes (Table 1) . The findings for cardiac myocytes, including the evidence that apoptosis occurs in response to the activation of β1-adrenoceptors (e.g., Singh et al 2001; Hasegawa et al 2001) , are implicated in the progression of heart failure and provide a rationale for the use of β-blockers to treat patients with heart failure (McMurray 2010). Table 2 summarizes examples of settings in which cAMP is anti-apoptotic, including its blockade of spontaneous apoptosis and apoptosis induced by a variety of agents. Agents that elevate cAMP (e.g., endogenous hormones or neurotransmitters, forskolin, PDE inhibitors or cAMP analogs) blunt apoptosis in numerous types of neurons, epithelial cells, in pancreatic islet β-cells and many other cell types.
Cells that show anti-apoptotic responses to cAMP

Can cAMP be pro-and anti-apoptotic in the same cell?
Certain cell types are listed in both Tables 1 and 2 . In some cases, this reflects the use of different cell lines derived from the same tissue, perhaps reflecting differences in the capacity of particular cell types in a given tissue to undergo pro-or anti-apoptosis in response to cAMP or the use of different experimental approaches, for example, whether spontaneous apoptosis is assessed or if a pro-apoptotic agent is added prior to assessing the impact of endogenous cAMP or a cAMP analog. Cell permeable cAMP analogs that are resistant to PDE inhibition can lead to sustained PKA activation and regulation of downstream targets. Elevation of endogenous cAMP by receptor activation generally produces more transient PKA activation due to receptor desensitization and PDE-mediated degradation of cAMP. Thus, different responses, both qualitatively and quantitatively, may occur with these two means of increasing cAMP.
In other cases, though, investigators use similar cell types but obtain different results. Although technical differences may contribute (especially since different methods are sometimes used to assay apoptosis and isolate and grow cells or in some cases, different cell isolates are employed in different studies), we believe that there is another explanation:
Individual cells may undergo both pro-apoptotic and anti-apoptotic responses to cAMP.
Results in a given experiment may thus depend on the conditions under which it is conducted (e.g, Chen et al 2002) . For example, murine S49 lymphoma cells, which undergo apoptosis in response to increased cAMP levels, in particular after 48-72 hr treatment Zhang and Insel 2001; Zhang and Insel 2004; Zambon et al 2005; Zhang et al 2008b) , show a transient anti-apoptotic response to cAMP (in terms of annexin V binding to phosphatidylserine on plasma membrane and caspase 3 activity; Figure 1 ) if also treated with certain pro-apoptotic agents (e.g., anti-Fas in Figure 1 and ultraviolet light, data not shown). Data from other laboratories also implicate cAMP as having pro-or anti-apoptotic activity in the same cell (e. 
Mechanisms for pro-and anti-apoptotic actions of cAMP
Different molecular mechanisms mediate cAMP-promoted pro-apoptosis and anti-apoptosis. Substantial evidence indicates that PKA is pro-apoptotic through the phosphorylation of protein targets (e.g., Zambon et al, 2005; Zhang et al 2008b; Benz et al 2008) . Studies in S49 lymphoma cells have shown that this pro-apoptotic effect of PKA occurs by an intrinsic, mitochondria-dependent mechanism Insel et al 1975; Yan et al 2000; Zhang and Insel 2004; Zambon et al 2005; Zhang et al 2008b) . The exact nature of the protein targets, in particular those that are necessary and sufficient to induce cAMP-promoted apoptosis, in wild-type S49 cells and other cell types has not yet been defined but is an area of active study.
Selective involvement of the two isozymes (I and II) of PKA may influence the role of cAMP in cell death. For example, cAMP analogs selective for the type I regulatory (R) subunit inhibit natural killer cell-mediated cytotoxicity (Torgresen et al 1997; Raskovalova et al, 2006) and expression of PKA type II R subunits can modulate apoptosis of fibroblasts (Porcellini et al 2003) . An altered balance between PKARI and RII has been implicated in various cancers; manipulation of these isozymes may be a means to enhance cAMPmediated apoptosis Bouizar et al 2010) .
In addition to being pro-apoptotic, PKA can also be anti-apoptotic, perhaps via effects that alter the balance of serine/threone phosphorylation of Akt by other kinases, such as p38 kinase and phosphatidylinositol 3-kinase (PI3 kinase) ( 
Potential therapeutic applications of the pro-and anti-apoptotic actions of cAMP
Information related to the ability of increases in cAMP to promote or block apoptosis may provide opportunities for new therapeutic approaches. Apoptosis is desirable in some settings (e.g., killing of neoplastic cells) but harmful in others (e.g., loss of pancreatic β-cells that leads to diabetes mellitus or of neurons, cardiac myocytes or epithelial cells following injury). Thus, one would seek to enhance cAMP/PKA-promoted apoptosis in cancer but blunt such apoptosis or increase cAMP/Epac-promoted anti-apoptosis in settings to maintain tissue integrity. Agents that target PKA will likely have undesirable side effects because of its widespread expression. Alternative approaches to exploit the pro-apoptotic role of PKA are by seeking to achieve specificity in PKA signaling, for example by targeting selectively expressed or subcellularly localized PKA R or C (catalytic) subunits, A kinase anchoring proteins (AKAPs) or phosphorylation targets of PKA.
The development of Epac-directed drugs or agents directed at Epac targets is an alternative approach that may yield novel ways to alter cAMP-regulated apoptosis, especially if used together with increases in cAMP in particular cell types or cellular compartments or that would regulate partners of Epac and PKA (e.g., Gao et al Savai et al 2010; Perrino et al 2010; Patel et al 2010) . Perhaps approaches that increase cAMP along with ones that inhibit Epac could provide combination therapies to supplement other types of antineoplastic agents (e.g., Desiniotis et al 2010), although one must be cautious since increased cAMP can blunt apoptosis by such agents in cancer cells (Naderi et al 2009; Safa et al 2010) .
Conclusions
Cyclic AMP can either promote or block apoptosis in a large number of cell types. The proapoptotic response to cAMP occurs via PKA and its phosphoylation of target proteins while the anti-apoptotic response may occur through the actions of Epac. Increasing insight regarding the pro-and anti-apoptotic actions of cAMP has the potential to identify new therapeutic approaches that may impact on a number of clinically important disorders. Desiniotis Wild-type S49 cells were incubated with 100μM CPT-cAMP, 500ng Anti-Fas or the combination of CPT-cAMP and Anti-Fas for 6h and 24h and then assayed for apoptosis (Annexin-V binding; left panel) or caspase 3 activity (determined using a colorometric assay kit from EMD; right panel). The results shown are from 3 separate experiments. *p<0.05, ** p<0.01 compared to control (0h), ## p<0.01 compared to anti-Fas alone by t-test analysis.
Note that CPT-cAMP blunts Annexin V binding and caspase 3 activity induced by anti-Fas treatment at 6 hr but this blunting is lost by 24h and that CPT-cAMP increases caspase 3 activity at 24 hr as a prelude to apoptosis Zhang et al, 2008b) . Table 1 Examples of cell types in which increases in cAMP are pro-apoptotic Cell Type Table 2 Examples of cell types in which increases in cAMP are anti-apoptotic
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